Search research articles
Contact Us
Filters
Showing results (1-10 of 41) with videos related to
Page
of 5
Sort By:
Seminars in Cancer Biology
|
September 19, 2017
Lung cancer epigenetics: From knowledge to applications
Michaël Duruisseaux, Manel Esteller
Annales De Pathologie
|
January 30, 2017
[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment]
Michaël Duruisseaux, Cécile Lize-Dufranc, Céline Badoual, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 13, 2024
Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal
Ali Chour, Clémence Basse, Fanny Lebossé, et al.
Bulletin Du Cancer
|
August 15, 2012
[Pulmonary sarcomatoid carcinoma]
Thibault Vieira, Michaël Duruisseaux, Anne-Marie Ruppert, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 7, 2009
Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features
Michaël Duruisseaux, Jacques Cadranel, Elisabeth Biron, et al.
ERJ Open Research
|
August 29, 2017
Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma
Michaël Duruisseaux, Nathalie Rabbe, Martine Antoine, et al.
Journal of Biomedical Science
|
April 17, 2026
Structure, mechanism and clinical relevance of NRG1 fusions in cancer
Clarisse Thiollier-Schmitt, Manon Barre, Marie Issenmann, et al.
Annales De Pathologie
|
February 7, 2017
[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers]
Michaël Duruisseaux, Isabelle Rouquette, Julien Adam, et al.
Radiation Oncology (London, England)
|
November 8, 2024
Prognostic value of neutrophil to lymphocyte ratio and lymphocyte counts before durvalumab consolidation after radio-chemotherapy in locally advanced non-small cell lung cancer
Arnaud Colomb, Benoit Allignet, Mehdi Lamkhioued, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 25, 2025
Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study
Romain Supiot, Alexandre Gherardi, Léopoldine du Manoir de Juaye, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 41) with videos related to
Sort By:
Page
of 5
Seminars in Cancer Biology
|
September 19, 2017
Lung cancer epigenetics: From knowledge to applications
Michaël Duruisseaux, Manel Esteller
Annales De Pathologie
|
January 30, 2017
[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment]
Michaël Duruisseaux, Cécile Lize-Dufranc, Céline Badoual, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 13, 2024
Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal
Ali Chour, Clémence Basse, Fanny Lebossé, et al.
Bulletin Du Cancer
|
August 15, 2012
[Pulmonary sarcomatoid carcinoma]
Thibault Vieira, Michaël Duruisseaux, Anne-Marie Ruppert, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 7, 2009
Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features
Michaël Duruisseaux, Jacques Cadranel, Elisabeth Biron, et al.
ERJ Open Research
|
August 29, 2017
Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma
Michaël Duruisseaux, Nathalie Rabbe, Martine Antoine, et al.
Journal of Biomedical Science
|
April 17, 2026
Structure, mechanism and clinical relevance of NRG1 fusions in cancer
Clarisse Thiollier-Schmitt, Manon Barre, Marie Issenmann, et al.
Annales De Pathologie
|
February 7, 2017
[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers]
Michaël Duruisseaux, Isabelle Rouquette, Julien Adam, et al.
Radiation Oncology (London, England)
|
November 8, 2024
Prognostic value of neutrophil to lymphocyte ratio and lymphocyte counts before durvalumab consolidation after radio-chemotherapy in locally advanced non-small cell lung cancer
Arnaud Colomb, Benoit Allignet, Mehdi Lamkhioued, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 25, 2025
Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study
Romain Supiot, Alexandre Gherardi, Léopoldine du Manoir de Juaye, et al.
Page
of 5